HRP20030894A2 - Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg - Google Patents

Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg Download PDF

Info

Publication number
HRP20030894A2
HRP20030894A2 HR20030894A HRP20030894A HRP20030894A2 HR P20030894 A2 HRP20030894 A2 HR P20030894A2 HR 20030894 A HR20030894 A HR 20030894A HR P20030894 A HRP20030894 A HR P20030894A HR P20030894 A2 HRP20030894 A2 HR P20030894A2
Authority
HR
Croatia
Prior art keywords
day
disorder
mammal
ocd
use according
Prior art date
Application number
HR20030894A
Other languages
English (en)
Croatian (hr)
Inventor
Stephen
Jonathan
Charles R Ashby Jr
Original Assignee
Brookhaven Science Ass Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brookhaven Science Ass Llc filed Critical Brookhaven Science Ass Llc
Publication of HRP20030894A2 publication Critical patent/HRP20030894A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20030894A 2001-05-14 2002-05-08 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg HRP20030894A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/853,392 US6462084B1 (en) 2001-05-14 2001-05-14 Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
PCT/US2002/014344 WO2002092071A1 (en) 2001-05-14 2002-05-08 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg

Publications (1)

Publication Number Publication Date
HRP20030894A2 true HRP20030894A2 (en) 2004-06-30

Family

ID=25315916

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030894A HRP20030894A2 (en) 2001-05-14 2002-05-08 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg

Country Status (18)

Country Link
US (2) US6462084B1 (enExample)
EP (1) EP1392273A4 (enExample)
JP (1) JP2004533445A (enExample)
KR (1) KR20040028758A (enExample)
CN (1) CN1509168A (enExample)
BR (1) BR0209614A (enExample)
CA (1) CA2446641A1 (enExample)
CZ (1) CZ20033379A3 (enExample)
HR (1) HRP20030894A2 (enExample)
HU (1) HUP0400032A3 (enExample)
IL (1) IL158761A0 (enExample)
MX (1) MXPA03010406A (enExample)
NO (1) NO20035037L (enExample)
NZ (1) NZ529613A (enExample)
PL (1) PL367362A1 (enExample)
TW (1) TWI313599B (enExample)
WO (1) WO2002092071A1 (enExample)
YU (1) YU89103A (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227052A1 (en) 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
JP2005534678A (ja) * 2002-06-27 2005-11-17 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 注意欠陥多動性障害の治療方法
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
WO2004096269A2 (en) * 2003-04-25 2004-11-11 Allergan, Inc. Botulinum neurotoxin for treating tics and obsessive compulsive behaviors
US20110275664A1 (en) * 2005-09-26 2011-11-10 The Regents Of The University Of Colorado,A Body Corporate Method for treating drug and behavioral addictions
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2790820A1 (en) * 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
AU2012345659B2 (en) 2011-12-02 2017-09-28 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014197744A1 (en) * 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN104306736A (zh) * 2014-10-31 2015-01-28 哈尔滨市海江科技开发有限公司 一种治疗疑病症的膏药及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761429A (en) 1985-07-22 1988-08-02 Kenneth Blum Enkephalinase and endorphinase inhibitors as anti-craving compositions
US5189064A (en) 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
US4786647A (en) 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
US4980168A (en) 1989-10-13 1990-12-25 Natrol, Inc. Dietary supplement for children
EP0767174A1 (de) 1991-11-21 1997-04-09 Ciba-Geigy Ag Neue Aminoalkanphosphinsäuren und ihre Salze
DK0641330T3 (da) * 1992-05-20 2001-12-03 Univ Northwestern Gaba- og L-glutaminsyreanaloger til antikrampeanfaldsbehandling
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
EP0915697B1 (en) 1996-06-28 2002-09-18 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
US5776956A (en) 1996-07-30 1998-07-07 Lectec Corporation Use of cotinine in treating psychiatric disorders
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
IL135659A0 (en) 1997-10-28 2001-05-20 Schering Corp Method of reducing craving in mammals
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
MXPA01004015A (es) * 1998-10-20 2003-03-10 Johnson & Johnson Derivados anticonvulsivos utiles para el tratamiento de la dependencia, adiccion y abuso del alcohol.
MXPA01007758A (es) 1999-02-01 2003-06-24 Johnson & Johnson Uso de derivados de anticonvulsivos para tratar la bulimia nerviosa.
NZ513643A (en) 1999-02-24 2005-04-29 Univ Cincinnati Use of sulfamate derivatives for treating impulse control disorders
AU4050100A (en) 1999-04-08 2000-11-14 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
AU2002227052A1 (en) * 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing

Also Published As

Publication number Publication date
CA2446641A1 (en) 2002-11-21
JP2004533445A (ja) 2004-11-04
NO20035037L (no) 2004-01-07
HUP0400032A3 (en) 2012-09-28
PL367362A1 (en) 2005-02-21
MXPA03010406A (es) 2004-05-05
WO2002092071A1 (en) 2002-11-21
BR0209614A (pt) 2004-12-07
YU89103A (sh) 2006-08-17
KR20040028758A (ko) 2004-04-03
NZ529613A (en) 2006-09-29
CZ20033379A3 (cs) 2004-12-15
EP1392273A4 (en) 2004-11-24
US20020169103A1 (en) 2002-11-14
HUP0400032A2 (hu) 2004-04-28
CN1509168A (zh) 2004-06-30
IL158761A0 (en) 2004-05-12
EP1392273A1 (en) 2004-03-03
NO20035037D0 (no) 2003-11-13
US6462084B1 (en) 2002-10-08
TWI313599B (en) 2009-08-21

Similar Documents

Publication Publication Date Title
Wright Pharmacologic effects of ketamine and its use in veterinary medicine
US5788986A (en) Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression using R enantiomers, S enantiomers, and racemic mixtures of selective serotonin reuptake inhibitor compounds or their active metabolites
EP0149545B1 (en) Pharmaceutical products providing enhanced analgesia
Essig Clinical and experimental aspects of barbiturate withdrawal convulsions
US6462084B1 (en) Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
SI21169A (sl) Nova uporaba peptidnega razreda spojine za zdravljenje alodinije ali drugih različnih vrst kronične ali fantomske bolečine
ES2220047T3 (es) Conbinacion de un antagonista selectivo de nmda nr2b y un inhibidor de la cox-2.
Kushida et al. Soft-diet feeding decreases dopamine release and impairs aversion learning in Alzheimer model rats
Barnes et al. Ionotropic glutamate receptor biology: effect on synaptic connectivity and function in neurological disease
CA2839350A1 (en) The use of serotonin receptor agonists for treatment of movement disorders
KR20020060192A (ko) Ｎｋ₁ 수용체 길항제와 ｇａｂａ 구조유사체의 상승적배합물
AU2002259153B2 (en) Novel treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
AU2002259153A1 (en) Novel treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
Avanzini et al. Epilepsy and Neurotransmitters Basis for a New Pharmacological Approach to Antiepileptic Therapy
US7737180B2 (en) Use of neboglamine (CR 2249) as an antipsychotic and neuroprotective
JP2008506630A (ja) ゾルピデムの更なる治療的使用
Zhang et al. Effects of 1, 1‐dimethylguanidine administration on blood pressure, heart rate and renal sympathetic nerve activity in normotensive and spontaneously hypertensive rats
Barnes et al. Effect of Genetic Background on Ionotropic Glutamate Receptor and Neurotrophin Biology: Synaptic Connectivity and Function in Neurological Disease
Barnes et al. Effect Connectivity Receptor of Genetic and and Background Neurotrophin Function in on Neurological Biology: Ionotropic Synaptic Glutamate
Ravenscroft Molecular and behavioural pharmacology of parkinsonism and associated dyskinesias
Sherif et al. Acute vigabatrin-phenobarbitone-interaction on exploratory behaviour of rats
Erhardt Importance of endogenous kynurenic acid in brainm catecholaminergic processes and in the pathophysiology of schizophrenia
Wari A Comparative Study Of The Anticonvulsant Effect Of Three Calcium Channel Blockers And Sodium Valproate In Albino Rats
Krantz Schedule-dependent behavioral effects following alteration of brain catecholamine levels with alpha-methyltyrosine and L-Dopa
EP1670468A1 (en) Use of npy y5 receptor antagonist for the treatment of circadian rhythm disorders

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODBI Application refused